Skip to content

Study · Not a test of the peptide alone · 2009

6 results

Immunotherapy improves immune homeostasis and increases survival rate of septic patients.

Huang SW, Chen J, Ouyang B, Yang CH, Chen MY, Guan XD

Chinese journal of traumatology = Zhonghua chuang shang za zhi1 Dec 2009Cited by 11 (Europe PMC)

PMID19930904 (opens in a new tab)PepBankPUB-19930904
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In postoperative septic patients, a regimen of ulinastatin plus thymosin-alpha(1) gave a higher survival rate (63.9%) than conventional therapy (41.2%).

    In plain wordsIn adults with sepsis after surgery, a treatment of ulinastatin plus thymosin alpha‑1 gave higher survival than conventional care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival rate (28-day)
    Study

    n = 70

    Comparator
    Conventional therapy
    Outcome group
    Mortality · Infection

    Measurements

    Survival rate
    63.9%
    immunotherapy group
    Survival rate
    41.2%
    conventional therapy group

    Source sentences

    Summary
    The survival rate was significantly higher in the immunotherapy group (63.9%; 23/36) compared with the conventional therapy group (41.2%; 14/34).
    1 context sentence
    Summary · context
    Seventy postoperative septic patients were divided into two groups at random: the immunotherapy group (n equal to 36) and the conventional therapy group (n=34).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In postoperative septic patients, a regimen of ulinastatin plus thymosin-alpha(1) gave lower serum TNF-alpha than conventional therapy (P less than 0.05).

    In plain wordsIn adults with sepsis after surgery, ulinastatin plus thymosin alpha‑1 was linked to lower TNF-alpha than conventional care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSerum TNF-alpha level
    Study

    n = 70

    Comparator
    Conventional therapy
    Outcome group
    Inflammation markers · Immune and inflammation

    Measurements

    Serum TNF-alpha
    1.38 ng/ml
    immunotherapy group
    Serum TNF-alpha
    1.88 ng/ml
    conventional group

    Source sentences

    Summary
    The serum TNF-alpha levels [(1.38+/-0.50) ng/ml in the immunotherapy group vs (1.88+/-0.53) ng/ml in the conventional group, P less than 0.05]
    1 context sentence
    Summary · context
    Seventy postoperative septic patients were divided into two groups at random: the immunotherapy group (n equal to 36) and the conventional therapy group (n=34).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In postoperative septic patients, a regimen of ulinastatin plus thymosin-alpha(1) gave higher serum IL-10 than conventional therapy (P less than 0.05).

    In plain wordsIn adults with sepsis after surgery, ulinastatin plus thymosin alpha‑1 was linked to higher IL-10 than conventional care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSerum IL-10 level
    Study

    n = 70

    Comparator
    Conventional therapy
    Outcome group
    Inflammation markers · Immune and inflammation

    Measurements

    Serum IL-10
    217.52 ng/ml
    immunotherapy group
    Serum IL-10
    101.53 ng/ml
    conventional group

    Source sentences

    Summary
    the serum IL-10 levels [(217.52+/-15.71) ng/ml vs (101.53+/-16.57) ng/ml, P less than 0.05]
    1 context sentence
    Summary · context
    Seventy postoperative septic patients were divided into two groups at random: the immunotherapy group (n equal to 36) and the conventional therapy group (n=34).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In postoperative septic patients, a regimen of ulinastatin plus thymosin-alpha(1) gave significantly higher serum IgG than conventional therapy.

    In plain wordsIn adults with sepsis after surgery, ulinastatin plus thymosin alpha‑1 was linked to higher IgG antibody levels than conventional care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSerum IgG level
    Study

    n = 70

    Comparator
    Conventional therapy
    Outcome group
    Immune response · Immune and inflammation

    Measurements

    Serum IgG
    17.65 g/L
    immunotherapy group
    Serum IgG
    11.94 g/L
    conventional group

    Source sentences

    Summary
    The serum IgG levels in the immunotherapy group [(17.65+/-6.81) g/L] were significantly higher than in the conventional group [(11.94+/-5.32) g/L].
    1 context sentence
    Summary · context
    Seventy postoperative septic patients were divided into two groups at random: the immunotherapy group (n equal to 36) and the conventional therapy group (n=34).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In postoperative septic patients, a regimen of ulinastatin plus thymosin-alpha(1) gave higher CD4+ T lymphocyte expression than conventional therapy (P less than 0.05).

    In plain wordsIn adults with sepsis after surgery, ulinastatin plus thymosin alpha‑1 was linked to more CD4+ T cells than conventional care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD4+ T lymphocyte expression
    Study

    n = 70

    Comparator
    Conventional therapy
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    CD4+ T lymphocyte (35%+/-13% in the immunotherapy group vs 21%+/-7% in the conventional group, P less than 0.05)
    1 context sentence
    Summary · context
    Seventy postoperative septic patients were divided into two groups at random: the immunotherapy group (n equal to 36) and the conventional therapy group (n=34).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In postoperative septic patients, a regimen of ulinastatin plus thymosin-alpha(1) gave higher CD14+ monocyte HLA-DR expression than conventional therapy (P less than 0.05).

    In plain wordsIn adults with sepsis after surgery, ulinastatin plus thymosin alpha‑1 was linked to higher monocyte HLA-DR than conventional care alone.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCD14+ monocyte HLA-DR expression
    Study

    n = 70

    Comparator
    Conventional therapy
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    CD14+ monocyte HLA-DR (50%+/-5% in the former vs 35%+/-4% in the latter, P less than 0.05).
    1 context sentence
    Summary · context
    Seventy postoperative septic patients were divided into two groups at random: the immunotherapy group (n equal to 36) and the conventional therapy group (n=34).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.